Enzo Biochem Operating Margin 2006-2021 | ENZ

Current and historical operating margin for Enzo Biochem (ENZ) over the last 10 years. The current operating profit margin for Enzo Biochem as of October 31, 2021 is 6.72%.
Enzo Biochem Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2021-10-31 $0.12B $-0.00B -1.72%
2021-07-31 $0.12B 0 0.00%
2021-04-30 $0.11B 0 0.00%
2021-01-31 $0.10B $-0.01B -12.37%
2020-10-31 $0.09B $-0.02B -25.88%
2020-07-31 $0.08B $-0.03B -39.47%
2020-04-30 $0.08B $-0.03B -41.56%
2020-01-31 $0.08B 0 0.00%
2019-10-31 $0.08B $-0.00B -1.25%
2019-07-31 $0.08B $0.00B 1.23%
2019-04-30 $0.08B $0.00B 1.20%
2019-01-31 $0.09B $-0.02B -27.27%
2018-10-31 $0.10B $-0.02B -18.95%
2018-07-31 $0.10B $-0.01B -12.87%
2018-04-30 $0.10B $-0.01B -7.77%
2018-01-31 $0.11B $-0.01B -4.76%
2017-10-31 $0.11B $-0.00B -2.86%
2017-07-31 $0.10B $-0.00B -2.88%
2017-04-30 $0.11B $0.04B 33.02%
2017-01-31 $0.11B $0.03B 30.48%
2016-10-31 $0.10B $0.04B 38.46%
2016-07-31 $0.10B $0.05B 44.66%
2016-04-30 $0.10B $0.02B 17.65%
2016-01-31 $0.10B $0.02B 18.00%
2015-10-31 $0.10B $0.01B 7.14%
2015-07-31 $0.10B $-0.00B -1.02%
2015-04-30 $0.10B $-0.01B -13.40%
2015-01-31 $0.10B $-0.01B -11.34%
2014-10-31 $0.10B $-0.01B -11.34%
2014-07-31 $0.10B $-0.01B -11.46%
2014-04-30 $0.09B $-0.01B -11.70%
2014-01-31 $0.09B $-0.02B -17.20%
2013-10-31 $0.09B $-0.02B -19.57%
2013-07-31 $0.09B $-0.02B -20.21%
2013-04-30 $0.10B $-0.05B -46.39%
2013-01-31 $0.10B $-0.04B -43.00%
2012-10-31 $0.10B $-0.04B -39.81%
2012-07-31 $0.10B $-0.04B -39.81%
2012-04-30 $0.10B $-0.02B -15.38%
2012-01-31 $0.10B $-0.01B -13.46%
2011-10-31 $0.10B $-0.02B -15.53%
2011-07-31 $0.10B $-0.01B -12.62%
2011-04-30 $0.10B $-0.02B -14.85%
2011-01-31 $0.10B $-0.02B -17.17%
2010-10-31 $0.10B $-0.02B -21.43%
2010-07-31 $0.10B $-0.02B -22.68%
2010-04-30 $0.10B $-0.02B -22.68%
2010-01-31 $0.10B $-0.02B -22.92%
2009-10-31 $0.09B $-0.02B -20.21%
2009-07-31 $0.09B $-0.02B -25.56%
2009-04-30 $0.09B $-0.02B -24.42%
2009-01-31 $0.08B $-0.02B -24.39%
2008-10-31 $0.08B $-0.02B -22.78%
2008-07-31 $0.08B $-0.02B -19.48%
2008-04-30 $0.07B $-0.02B -21.62%
2008-01-31 $0.07B $-0.02B -26.09%
2007-10-31 $0.06B $-0.02B -32.26%
2007-07-31 $0.05B $-0.02B -39.62%
2007-04-30 $0.05B $-0.02B -48.89%
2007-01-31 $0.04B $-0.02B -53.66%
2006-10-31 $0.04B $-0.02B -52.50%
2006-07-31 $0.04B $-0.02B -52.50%
2006-04-30 $0.04B $-0.03B -80.49%
2006-01-31 $0.04B $-0.03B -73.81%
2005-10-31 $0.04B $-0.03B -60.47%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.154B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00